Skip to content

0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis

The Effect of 0,9% NaCl on the Kidney Function, Vasoactive Hormones, Biomarkers and Glycosaminglycanes in Plasma in Patients Operated on for Primary Hiparthrosis

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02528448
Acronym
KIPA
Enrollment
40
Registered
2015-08-19
Start date
2015-03-31
Completion date
2016-02-29
Last updated
2015-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotoxicity

Keywords

Vasoactive hormones, bio markers, salt regulation, Renal variables

Brief summary

The purpose of this study is to determine if chloride is nephrotoxic using 0,9% saline versus Plasma-Lytein in patients having primary hip replacement surgery. The outcome is found measuring bio markers, vasoactive hormones and salt regulation. And to measure syndecan as a marker for glycocalyx degradation.

Detailed description

Hypothesis: Chloride has a nephrotoxic effect, which can be shown partially by measuring bio markers for tubular injury in urine, partially by the changes in tubular transport of sodium and water in different parts of the nephron. This can be demonstrated using isotone sodium solutions with a lower chloride concentration in this study plasma-lyte versus normal isotone saline. Klorid has a toxic effect on the glycocalyx layer and leads to a rise in syndecan 1 and simultaneously a change in Salt Blood Test either by a direct simulation and ANP levels in plasma or as a consequence of the hyperchloremic acidosis. This can be demonstrated using isotone sodium solutions with a lower chloride concentration in this study plasma-lyte versus normal isotone saline. Purpose: The purpose is to observe changes in bio markers, vasoactive hormones and salt regulation in patients randomized to either 0,9% saline or plasma-lyte undergoing primary uncemented hip replacement surgery. Design: 40 patients undergoing primary uncemented hip replacement surgery will be randomized to either 0,9% saline or plasma-lyte for standard fluid resuscitation and blood loss replacement in this controlled and double blinded study. The patients will deliver a 24 hour urine sample before surgery and approximately 10 days after. From the start of the surgery and to the day after all urine will be collected and blood samples will be taken. Perspective: If chloride is found to be nephrotoxic it could lead to a general change in fluid resuscitation recommendations in critically ill patient, patients with kidney disease and patients undergoing surgery. It will also expand our knowledge about the permeability of the blood vessels.

Interventions

Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement

Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement

Sponsors

Regional Hospital Holstebro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Indication for uncemented primary hiparthroplasty * age \< 60

Exclusion criteria

* Blooddonation or transfusion during the last month * Not willing to participate * estimated GFR below 30ml/min * type 1 diabetes

Design outcomes

Primary

MeasureTime frame
Urinary excretion of Neutrophil gelatinase-associated lipocalintwo days

Secondary

MeasureTime frame
Plasma concentration of aldosteronetwo days
Plasma concentration of atrial natriuretic peptide (ANP)two days
Plasma concentration of brain natriuretic peptide (BNP)two days
Plasma concentration of cyclic guanosine monophosphate (cGMP)two days
Plasma concentration of endothelintwo days
Plasma concentration of vasopressin (AVP, ADH)two days
Urinary excretion of Fatty acid-binding proteintwo days
Urinary excretion of Kidney Injury Moleculetwo days
Free water clearancetwo days
Plasma concentration of albumintwo days
Plasma concentration of chloridetwo days
Plasma concentration of creatininetwo days
Plasma osmolaritytwo days
Plasma concentration of sodiumtwo days
Plasma concentration of potassiumtwo days
Plasma concentration of angiotensin 2two days
Urinary excretion of chloridetwo days
Urinary excretion of sodiumtwo days
Urinary excretion of potassiumtwo days
Fractional urinary sodium excretiontwo days
Urinary osmolaritytwo days
Urinary excretion of albumintwo days
Urinary excretion of sodium-chloride symportertwo days
pHtwo days
pulsetwo days
middle arterial pressuretwo days
plasma Syndecan-1two days
plasma renin concentrationtwo days
Urinary excretion of cyclic guanosine monophosphatetwo days
Urinary excretion of epithelial sodium channelstwo days
Urinary excretion of water channelstwo days
Urinary excretion of creatininetwo days

Countries

Denmark

Contacts

Primary ContactAndreas N Jørgensen, MD
andrjr@rm.dk78436589

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026